- Genentech announced positive results from its Phase 3 Archway study. Archway examined the effects of Genentech’s Port Delivery System with ranibizumab (PDS), which can potentially reduce treatments from 12 to two times a year for patients with neovascular AMD. Among the key findings, 98.4% of PDS patients were able to go 6 months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections. The results will be discussed virtually during the 38th Annual Meeting of the American Society of Retina Specialists on Sunday, July 26.
- Bausch + Lomb announced its new Pinnacle 360 25-gauge Scleral Fixation Forceps. The scleral fixation forceps are designed to aid in the placement of scleral-sutured posterior chamber IOL, a procedure used in the treatment of aphakic eyes without capsule support. The forceps feature ergonomic 360° actuation and glare-free tips that promote traction through the use of microserrated edges.
- MeiraGTx shared 6-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR. AAV-RPGR is an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant improvement in vision was demonstrated in the dose escalation phase of the trial, and AAV-RPGR was found to be generally well tolerated. Data from the trial will be presented virtually at the 38th Annual Meeting of the American Society of Retina Specialists on Sunday, July 26.
- Two digital pharmacies, Medley Pharmacy and NowRx, secured additional funding to expand their operations. Medley Pharmacy received a $100 million series B funding, which it will use to expand its initial five pharmacies – located in New York, New Jersey, Pennsylvania, Maryland and Florida – to locations in most metropolitan cities. Medley Pharmacy provides on-demand, same-day prescription delivery, files insurance claims and helps manage patient adherence and refills. NowRx, which also supplies free, same-day, door-to-door prescription delivery to customers, secured $20 million in a new round of funding. NowRx, which has four fullfilment centers in California and a fifth opening in Arizona, plans to use the funds to improve its proprietary pharmacy management software and logistics technology and open more fulfilment centers in other territories.
Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here.